Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Yamo’s L1-79 misses statistical significance
June 2019
SHARING OPTIONS:

NEW YORK—May saw Yamo Pharmaceuticals LLC share results from its Phase 2 study of L1-79 for the treatment of autism spectrum disorder (ASD) at the International Society for Autism Research Annual Meeting. The randomized, double-blind, placebo-controlled study consisted of 31 male patients between the ages of 13 and 21 who had been diagnosed with ASD. Participants received either 100 mg of L1-79, 200 mg of L1-79 or placebo, administered three times a day for 28 days. Those in the L1-79 cohorts showed trends in improvement in social functioning and repetitive restrictive behaviors compared to the placebo group, though results did not reach statistical significance. Yamo intends to move forward with a larger study in adolescents and young adults with ASD.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.